Different combinations of oncogene activation in cancer cells can affect patient outcomes. Specifically, in this study led by N2CR member Dr Anand Jeyasekharan, the authors looked at a type of cancer called diffuse large B-cell lymphoma (DLBCL) and used microscopic imaging to identify a specific combination of oncogene expression that consistently predicted survival across multiple patient groups. They also proposed a way to estimate gene expression from patient samples that could help predict outcomes and identify new targets for therapy. The hope is that this research will lead to better ways of predicting and treating cancer, ultimately improving patient outcomes.

Read more here: https://pubmed.ncbi.nlm.nih.gov/37071673/